AustralieFrV1, PubMed, Corpus, bibRecord, 000093

Predictive factors for successful renal denervation: should we use them in clinical trials?

Identifieur interne : 000093 ( PubMed/Corpus ); précédent : 000092; suivant : 000094

Predictive factors for successful renal denervation: should we use them in clinical trials?

Auteurs : Nicolas Barber-Chamoux ; Murray D. Esler

Source :

European journal of clinical investigation [ 1365-2362 ] ; 2017.

RBID : pubmed:28771706

Abstract

Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.

DOI: 10.1111/eci.12792
PubMed: 28771706

Links to Exploration step

pubmed:28771706

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictive factors for successful renal denervation: should we use them in clinical trials?</title>
<author><name sortKey="Barber Chamoux, Nicolas" sort="Barber Chamoux, Nicolas" uniqKey="Barber Chamoux N" first="Nicolas" last="Barber-Chamoux">Nicolas Barber-Chamoux</name>
<affiliation><nlm:affiliation>Cardiology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Esler, Murray D" sort="Esler, Murray D" uniqKey="Esler M" first="Murray D" last="Esler">Murray D. Esler</name>
<affiliation><nlm:affiliation>Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28771706</idno>
<idno type="pmid">28771706</idno>
<idno type="doi">10.1111/eci.12792</idno>
<idno type="wicri:Area/PubMed/Corpus">000093</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000093</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Predictive factors for successful renal denervation: should we use them in clinical trials?</title>
<author><name sortKey="Barber Chamoux, Nicolas" sort="Barber Chamoux, Nicolas" uniqKey="Barber Chamoux N" first="Nicolas" last="Barber-Chamoux">Nicolas Barber-Chamoux</name>
<affiliation><nlm:affiliation>Cardiology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Esler, Murray D" sort="Esler, Murray D" uniqKey="Esler M" first="Murray D" last="Esler">Murray D. Esler</name>
<affiliation><nlm:affiliation>Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">European journal of clinical investigation</title>
<idno type="eISSN">1365-2362</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28771706</PMID>
<DateCreated><Year>2017</Year>
<Month>08</Month>
<Day>03</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>10</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>47</Volume>
<Issue>11</Issue>
<PubDate><Year>2017</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>European journal of clinical investigation</Title>
<ISOAbbreviation>Eur. J. Clin. Invest.</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictive factors for successful renal denervation: should we use them in clinical trials?</ArticleTitle>
<Pagination><MedlinePgn>860-867</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.12792</ELocationID>
<Abstract><AbstractText>Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.</AbstractText>
<CopyrightInformation>© 2017 Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barber-Chamoux</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-3771-9807</Identifier>
<AffiliationInfo><Affiliation>Cardiology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Esler</LastName>
<ForeName>Murray D</ForeName>
<Initials>MD</Initials>
<AffiliationInfo><Affiliation>Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Heart Centre, Alfred Hospital, Melbourne, Vic., Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>10</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Eur J Clin Invest</MedlineTA>
<NlmUniqueID>0245331</NlmUniqueID>
<ISSNLinking>0014-2972</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword>
<Keyword MajorTopicYN="N">hypertension</Keyword>
<Keyword MajorTopicYN="N">renal denervation</Keyword>
<Keyword MajorTopicYN="N">sympathetic nervous system</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>01</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>07</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28771706</ArticleId>
<ArticleId IdType="doi">10.1111/eci.12792</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000093 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000093 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:28771706
   |texte=   Predictive factors for successful renal denervation: should we use them in clinical trials?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:28771706" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Predictive factors for successful renal denervation: should we use them in clinical trials?

Predictive factors for successful renal denervation: should we use them in clinical trials?

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki